A phase I study evaluating the combination of OSI-906, a dual inhibitor of insulin growth factor-1 receptor (IGF-1R) and insulin receptor (IR) with weekly paclitaxel (PAC) in patients with advanced solid tumors.Wael A. Harb, Srinivasu Poondru, David Sternberg et al.|Journal of Clinical Oncology|2011Cited by 7
Phase I dose-finding study of trabectedin (T) in combination with cisplatin (C) in patients (pts) with advanced solid tumors.C. Sessa, Luca Gianni, Elisa Gallerani et al.|Journal of Clinical Oncology|2011Cited by 0